SEC Filing | Ardelyx, Inc.
Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
🦍💎 $ARDX ✋🚀
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Ardelyx (@ardelyx) / X
ARDX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 28, 2021 in the Class Action Filed on Behalf of Ardelyx, Inc. Limited Shareholders
Scripts : r/ARDELYX
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF | Chronic Kidney Disease | Therapy
Hyperphosphatemia Pipeline Insight Report 2023 (Updated)
AFTER HOUR TRADING IS HALTED : r/ARDELYX
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Ardelyx to Raise $110 Million in a Private Placement
Ardelyx
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
SEC Filing | Ardelyx, Inc.
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Positive FDA AdCom votes for Ardelyx's tenapanor
ARDX / Ardelyx, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ardelyx, Inc. (ARDX) Investigation
Ardelyx wins FDA approval for phosphate absorption inhibitor - Pharmaceutical Technology
Ardelyx Grants Stock Options & RSUs to New Employees
News & Events | Ardelyx, Inc.
